{"id":11101,"date":"2025-07-27T11:57:30","date_gmt":"2025-07-27T09:57:30","guid":{"rendered":"https:\/\/valintermed.com\/?p=11101"},"modified":"2025-07-27T11:57:30","modified_gmt":"2025-07-27T09:57:30","slug":"endokardialnyy-fibroelastoz","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/endocardial-fibrosis\/","title":{"rendered":"Endocardial fibroelastosis"},"content":{"rendered":"
<\/div>\n

Endocardial fibroelastosis (EFE) is a cardiac pathology characterized by hypertrophy and fibrosis of the endocardial tissue, which impairs the functionality of the heart, especially its right chambers. This disease is most often observed in children, but it can also occur in adults. EFE manifests itself as cardiac insufficiency, arrhythmias, and can also be accompanied by signs of systemic failure and life-threatening conditions. One of the key features of EFE is its idiopathic nature, but in some cases it can develop against the background of other cardiac diseases or as a result of genetic disorders.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n